MarginsXMarginsX
Home › Markets › Health Care › EDIT

Editas Medicine Inc. (EDIT)

EDIT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.87
-13.82% on the day
Market cap
$288.6M
Micro cap
Revenue · 2025
$40.5M
+25.4% on 2024
Net income · 2025
-$160.1M
-395.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/0001650664-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerEDIT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2016
SEC CIK0001650664
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$40.5M
Net income-$160.1M
Operating income-$160.0M
Net margin-395.0%
Operating margin-394.9%
Revenue growth+25.4%
Cash$146.6M
Total assets$186.5M
P/E (computed)Net income was not positive
P/S (computed)7.1×

Warning signs

Cash runway
10.1 months
$93.2M cash at September 30, 2026
Share count, 1 year
+58.1%
2025-10-31 to 2026-11-06 · +89.0% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$107K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$93.2M cash; operating cash flow -$27.6M a quarter.Report 2026-09-30
Shares outstanding154,339,748 (2026-11-06); 97,618,660 a year earlier; 81,673,688 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the marketLatest 2026-05-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months8-K 4.01 2026-04-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $107K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$10.4M-$23.4M-$21.2M$93.2M$56.8M$49.8M10-Q 2026-11-09
Q2 2026
2026-06-30
$11.9M-$18.2M-$29.6M$181.8M$55.7M$47.0M10-Q 2026-08-05
Q1 2026
2026-03-31
$2.8M-$25.0M-$23.1M$123.6M$54.7M$38.7M10-Q 2026-05-05
Q4 2025
2025-12-31
$24.7M-$5.6M-$36.4M$146.6M$58.6M$40.5M10-K 2026-03-09
Q3 2025
2025-09-30
$7.5M-$25.1M-$30.8M$165.6M$59.1M$46.4M10-Q 2026-11-09
Q2 2025
2025-06-30
$3.6M-$53.2M-$50.2M$138.5M$56.7M$38.9M10-Q 2026-08-05
Q1 2025
2025-03-31
$4.7M-$76.1M-$47.8M$138.7M$54.6M$35.8M10-Q 2026-05-05
Q4 2024
2024-12-31
$30.6M-$45.4M-$50.8M$131.5M$57.4M$32.3M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-08-31
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 733 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.6%
1 month-11.2%
3 months-22.8%
Year to date+5.9%
1 year-14.6%
From 52-week high-42.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
XFORX4 Pharmaceuticals Inc.$2.83-9.29%$289.0M
SCTXScribe Therapeutics Inc.$15.37-6.05%$291.1M
EIKNEikon Therapeutics Inc.$5.38-9.95%$291.8M
AGENAgenus Inc.$6.29-6.54%$284.6M
AGMBAgomAb Therapeutics NV$5.97-6.13%$294.0M
TRXBTRex Bio Inc.$10.77-21.21%$295.6M
IPSCCentury Therapeutics Inc.$1.64-0.61%$297.8M
ALLOAllogene Therapeutics Inc.$0.8070-3.78%$279.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier